Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mannose 6-Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannose 6-Phosphate SCHEMBL28885847 | 1.00 | MPI (0.52) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL2387370 | 1.00 | MPI (0.52) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21632784 | 1.00 | MPI (0.52) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL9231707 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21693684 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21693687 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21693710 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21693713 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL9234969 | 0.98 | MPI (0.50) | MPIPGD | |
| Mannose 6-Phosphate SCHEMBL21693697 | 0.98 | MPI (0.50) | MPIPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122032323-A | Sodium glucose phosphate modified nanofiltration membrane and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-119263766-A | White surface gypsum and preparation method and application thereof | 山东汉诺宝嘉新材料科技有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-117965679-A | G6PD enzyme activity detection kit and preparation method thereof | 深圳市亿立方生物技术有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-114920765-B | Aryl boric acid substituted cationic porphyrin array sensor and preparation method and application thereof | 南京农业大学 | 2024-02-06 | — | — | CN | claimed |
| CN-117451888-A | Method for detecting atherosclerosis disease glycometabolism marker based on liquid chromatography-mass spectrometry | 重庆医科大学 | 2024-01-26 | — | — | CN | claimed |
| CN-114505064-B | Synthesis method and application of manganese-doped zinc sulfide quantum dot of glucose-6-phosphate | 常州磐诺仪器有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-115166131-A | Method for detecting in-vitro DNA adduct catalyzed by drug metabolizing enzyme through single-molecule manipulation | 华中科技大学 | 2022-10-11 | — | — | CN | claimed |
| CN-114920765-A | Aryl boric acid substituted cationic porphyrin array sensor and preparation method and application thereof | 南京农业大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114505064-A | Synthesis method and application of manganese-doped zinc sulfide quantum dots of glucose-6-phosphate | 常州磐诺仪器有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-113292880-A | High-weather-resistance flame-retardant super-amphiphobic coating capable of being adhered to surface of substrate and construction method thereof | 四川大学 | 2021-08-24 | — | — | CN | claimed |
| EP-1278551-A2 | COMPOSITIONS AND METHODS FOR (IN VIVO) DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020019358-A1 | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics | VICAL INCORPORATED | 2002-02-14 | — | — | US | claimed |
| WO-2001080897-A2 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2001-11-01 | — | — | WO | claimed |
| US-12629390-B2 | Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions | AMORPHICAL LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| CN-122032323-A | Sodium glucose phosphate modified nanofiltration membrane and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-15 | — | — | CN | disclosed |
| CN-122032323-A | Sodium glucose phosphate modified nanofiltration membrane and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-15 | — | — | CN | disclosed |
| US-4190496-A | RECEPTOR, LIGAND, AND ENZYME-BOUND | SYVA COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4156081-A | IMMUNOASSAYING | SYVA COMPANY (US) | 1979-05-22 | — | — | US | disclosed |
| US-4040907-A | CHANGE IN ENZYMATIC ACTIVITY ON BINDING | SYVA COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-3931402-A | Preparations containing hexoses | SOCIETA PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629390-B2 | Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions | SMN1; SMN2, CACNA2D1, CACNA2D3 | MPI 801/4885PGD 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.